Fluorouracil

Evidence Level: L5

Predicted Indications: 10

Fluorouracil

Pharmacist Assessment Report

Fluorouracil: Botryoid-type embryonal rhabdomyosarcoma of the vagina

One-Sentence Summary

Fluorouracil is an antimetabolite chemotherapy drug. It is recorded for skin conditions (such as actinic keratosis and basal cell carcinoma), colon cancer metastases, pancreatic adenocarcinoma and gastric cancer. The TxGNN model (deep learning) predicts it may be effective for botryoid-type embryonal rhabdomyosarcoma of the vagina (score 0.9975); this score comes from the model and may reflect similarities the model learned between related diseases, not biological evidence. No clinical trials and only 4 loosely related publications (old reviews, a cohort report and a single case report) are available, so the evidence is model-prediction level only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Botryoid-type embryonal rhabdomyosarcoma of the vagina
TxGNN Prediction Score	0.9975
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, fluorouracil is a thymidylate synthase inhibitor and antimetabolite that disrupts DNA and RNA synthesis in rapidly dividing cells. Its established role in gastrointestinal cancers suggests it could, in principle, act on other fast-proliferating tumours such as sarcomas.

Rhabdomyosarcoma is a proliferative soft-tissue sarcoma. The prediction is therefore biologically plausible, but it comes from the TxGNN model (deep learning) only and may reflect similarities the model learned between related diseases, not biological evidence. The top-ranked subtypes (vaginal botryoid-type, parameningeal, bile duct and prostate embryonal rhabdomyosarcoma) have no trials or publications at all.

The literature on general rhabdomyosarcoma does not isolate any fluorouracil-specific effect. Fluorouracil appears only within multi-agent regimens or general chemotherapy overviews.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

None of these studies directly tests fluorouracil in rhabdomyosarcoma. They are indirect. Assessment is based on titles and abstract excerpts only.

PMID	Year	Type	Journal	Key Findings
3884137	1985	Review	Cancer	Overview of adjuvant chemotherapy for childhood sarcomas, including rhabdomyosarcoma
42483493	2026	Case report	Case Reports in Oncological Medicine	Adult lingual rhabdomyosarcoma. Cisplatin plus 5-fluorouracil was one of the regimens used, and the disease progressed on it. A later vincristine/actinomycin D-based regimen was used
3951398	1986	Cohort	Medical and Pediatric Oncology	Childhood nasopharyngeal carcinoma (not rhabdomyosarcoma), so only loosely related
6277228	1981	Review	Annals of the Academy of Medicine, Singapore	General overview of chemotherapy curability in advanced cancers, mentioning rhabdomyosarcoma

India Market Information

At least 20 single-ingredient injectable fluorouracil approvals are listed, and the list may be partial. The licence records contain no approved-indication text. The five main entries are:

Authorization Number	Product Name	Dosage Form	Approved Indication
91285	Fivoflu 250mg Injection	Vial of 5 ml injection	Not stated in the record
90158	Fivotop 500 Injection	Ampoule of 10 ml injection	Not stated in the record
85231	Fluracil 500mg Injection	Vial of 10 ml injection	Not stated in the record
91059	Flocil 250mg Injection	Vial of 5 ml injection	Not stated in the record
87925	Fivocil 500mg Injection	Vial of 5 ml injection	Not stated in the record

All listed products are injections. Whether this route suits rhabdomyosarcoma has not been assessed.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (fluoropyrimidine antimetabolite)
Emetogenicity Classification	Low to medium
Monitoring Items	Complete blood count with differential, liver and renal function. Mucositis and diarrhoea should also be monitored
Handling Protection	Must follow cytotoxic drug handling regulations

Please also refer to the package insert warnings and precautions.

Safety Considerations

Contraindications recorded in the knowledge graph (not label text): kidney disease, liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, leukopenia, diarrhoeal disease, active peptic ulcer disease, stomatitis, pharyngitis, pyoureter and dihydropyrimidine dehydrogenase (DPD) deficiency.
Drug interactions: 361 interactions were found in total. Moderate-level examples are metronidazole and tinidazole. Minor-level examples are cimetidine and levofloxacin. Many others are of unknown severity (such as omeprazole, pantoprazole, metformin and morphine).

Package insert warnings were not available in the data compiled for this report. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but no clinical trial and no fluorouracil-specific publication directly supports rhabdomyosarcoma, so the evidence level is L5. The drug is marketed in India, but only as an injectable with no indication text on record. Its myelosuppressive toxicity also calls for caution.

To proceed, the following is needed:

A targeted search for studies of fluorouracil-containing regimens in rhabdomyosarcoma, with full-text review
Mechanism of action data and the package insert warnings and contraindications
Confirmation of the approved indications on the Indian licences
Assessment of route and dosage-form fit for the target population, which is largely paediatric
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.